Global Artificial Intelligence Pathology Diagnosis Market: Key Trends & Opportunities According to a newly published market research report by 24LifeSciences, global inflammatory bowel disease treatment market is valued at USD 13.03 billion in 2026 and is projected to reach USD 15.41 billion by 2034, growing at a compound annual growth rate (CAGR) of 2.5% during the forecast period. Inflammatory Bowel Disease (IBD) treatments encompass a comprehensive range of therapeutics designed to manage chronic inflammatory conditions primarily affecting the gastrointestinal tract, including Crohn's disease and ulcerative colitis. These treatments are meticulously developed to induce and maintain remission, alleviate debilitating symptoms, and improve patients' quality of life. The market features several key drug classes: aminosalicylates, which serve as effective first-line therapy for mild-to-moderate cases; TNF inhibitors, a class of advanced biologics that precisely target the tumor necrosis factor-alpha pathway; corticosteroids for their potent anti-inflammatory effects during acute flare-ups; and immunomodulators, which work by modifying the abnormal immune response characteristic of these conditions. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9181/inflammatory-bowel-disease-treatment-market

Rising GI Disorders Driving the Malabsorption Syndrome Market Worldwide According to a newly published market research report by 24LifeSciences, global malabsorption syndrome market value is at USD 8.5 billion in 2026 and is projected to reach USD 13.2 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.4% during the forecast period. Malabsorption syndrome encompasses a group of disorders where the small intestine is unable to properly absorb sufficient amounts of critical nutrients and fluids from ingested food, leading to deficiencies in macronutrients like proteins, carbohydrates, and fats, as well as vital micronutrients including essential vitamins and minerals. This complex condition, often arising secondary to chronic gastrointestinal diseases, demands a multifaceted therapeutic approach that combines targeted pharmaceuticals with specialized nutritional support, underlining its significant clinical and economic impact on global healthcare systems. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9520/malabsorption-syndrome-market

Global GIST Market Shows Steady Expansion Driven by Targeted Oncology Therapies Global gastrointestinal stromal tumor (GIST) market is demonstrating sustained growth as advances in molecular oncology and targeted therapies continue to redefine treatment standards. Valued at USD 1.08 billion in 2024, the market is projected to grow from USD 1.15 billion in 2025 to USD 1.76 billion by 2032, expanding at a CAGR of 5.8% during the forecast period. This upward trajectory reflects increasing diagnostic accuracy, wider access to tyrosine kinase inhibitors, and a growing emphasis on personalized cancer care worldwide. Access the complete report https://www.24lifesciences.com/gastrointestinal-stromal-tumor-market-9149

What Is the Future of the Gastritis Treatment Market? Growth Forecasts & Insights Global gastritis treatment market is demonstrating consistent growth as gastrointestinal disorders gain greater clinical attention worldwide. Valued at approximately USD 4.5 billion in 2024, the market is projected to expand from USD 4.8 billion in 2025 to USD 6.9 billion by 2031, registering a compound annual growth rate (CAGR) of 5.3% during the forecast period. This upward trajectory is driven by the high prevalence of Helicobacter pylori infection, lifestyle-related risk factors, and increasing reliance on long-term pharmacological management for chronic gastric conditions. Access the report https://www.24lifesciences.com/gastritis-treatment-market-9033